Recently, Jiangsu Baishaifei Biotechnology Co., Ltd. (hereinafter referred to as "Baishaifei") officially announced the completion of a new round of financing. This round of financing is led by Jin Yu Mao Gou, with veteran shareholders leading venture capital and leading New Territories to increase equity.
This round of financing will further promote Baisaifei's comprehensive acceleration of technological innovation and market globalization process: by adding advanced surface modification technology, it will create an internationally leading high-performance coating platform; Relying on a one-stop solution for functional coatings, we will promote the large-scale production and market launch of innovative downstream equipment with special functional coatings, achieving industrial chain supplementation and independent controllability; Combining the foundation of automated equipment manufacturing with AI technology, expanding international ODM factories and forming global service capabilities; And based on the big language model, an intelligent operation and maintenance management system is developed to improve operational and service efficiency.
Professor Chen Hong, founder of Baisai Fei, said, "The completion of the new round of financing is another new starting point. We will use the triple leap of 'technology+production capacity+intelligence' to make high-performance coatings the carrier and promote China's innovation to the world.
Wang Qun, the head of Jinyu Maogou Investment, said: "Baisaifei is a rare technology platform enterprise in China that not only has leading surface modification technology, but also has solid industrialization achievements. With its founder Professor Chen Hong as the core, the highly educated, international, strong execution, and interdisciplinary team has been deeply involved in the high-end biomaterials industry for many years, forming a strong know-how system for surface modification technology research and development and an intelligent and efficient operation management system. It has achieved import substitution and surpassing in the bottleneck links of multiple strategic emerging industries. We believe and look forward to Baisai Fei becoming an industry champion enterprise with international competitiveness and influence.
Leading venture capital firm Tao Shanshan said, "Based on the academic high ground, Baisaifei has built a full chain medical functional coating industrialization platform from basic research to industrial level services, which has outstanding significance for breaking the import monopoly and realizing the independent and controllable development of China's medical device industry chain. We look forward to Baisaifei further strengthening its research and development strength and channel construction, and becoming a leading enterprise in the field of medical device raw materials in China and internationally advanced as soon as possible.
Li Qiuxuan, Vice President of Leading New Territories, said, "Baisaifei has been deeply involved in the field of biomaterials surfaces and interfaces for many years. Under the leadership of Professor Chen Hong, we have built a full industry chain technology service platform covering hydrophilic lubrication, antibacterial and anticoagulant coatings. With solid research and development, we have broken foreign monopolies and achieved import substitution in key areas. Leading New Territories continues to accompany us, and this additional investment hopes to support our team in exploring a wider range of medical scenarios and cross disciplinary applications. We look forward to Baisaifei continuing to use technological innovation as the anchor point to help China's medical device industry develop to higher quality.
Jiangsu Baisaifei Biotechnology Co., Ltd. is a national "specialized, refined, and innovative" small giant enterprise in the field of surface modification technology for biomaterials. Since its establishment in 2017, it has undergone multiple rounds of financing and expansion, and now has nearly 25000 square meters of research and development and production sites. It has taken the lead in creating a technical service platform for the entire functional coating industry chain, covering independently developed multiple series of medical coating products (including hydrophilic lubrication, anticoagulant, antibacterial, anti crystallization, drug release and other categories), automated coating equipment/production lines, coating AI quality inspection and analysis instruments. It is the enterprise with the most medical coating related patents in China and has won the 2024 China Patent Award. At the same time, it has led the establishment of the first industry standard related to the firmness of medical device coatings in China, and has filled multiple gaps in the domestic market. The release of group standards related to anticoagulant, antibacterial and other medical coatings; We have established a few large-scale production bases for medical coatings that meet the dual standards of hazardous chemicals and medical supplies in China. Hundreds of medical device manufacturers have obtained NMPA, FDA, or CE medical device registration certificates for their products using Baisai Fei coatings.
Regarding Jinyu Maogu:
Jinyu Maogu Investment Management Co., Ltd. (stock code: 834960) is a venture capital institution officially listed on the New Third Board; Ranked 22nd in China's venture capital institutions, top 10 in the new materials field, top 30 in the semiconductor field, top 20 in the most active institutions in the medical and health field, 22nd in the real money exit list, and 14th in the specialized and innovative GP list, and was honored as the leading enterprise of Jiangsu Province's venture capital brand and excellent team of Jiangsu Province's venture capital. The company's fund management scale exceeds 20 billion yuan, and has invested in more than 300 strategic emerging industries such as new materials and intelligent manufacturing, new energy and ecological environment, new medicine and big health, semiconductors and innovative technology, and has obtained more than 30 IPOs. The medical, pharmaceutical, and health industry is one of the main core investment areas of Jinyu Maoguo. The invested medical projects include Betaine (300957), Zhaoyan New Drug (603127), Wanbangde (002082), Nodai Biotechnology (688076), Shutai Shen (300204), PharmarStone Technology (300725), Nearshore Protein (688137), Zhiyuan Pharmaceutical, Xuankai Biotechnology, Weiqi Pharmaceutical, etc.
Regarding Leading Venture Capital:
Leading Venture Capital was established in December 2012 with a registered capital of 387.5 million yuan. Its managed funds include the Park Science and Technology Innovation Fund, Park Guidance Fund, and Leading Yuanrui Financial Technology Fund, with a fund management scale of approximately 3 billion yuan. It is currently the largest policy angel investment institution in Suzhou Industrial Park and has played an active role in assisting the park in introducing high-end talents, promoting rapid enterprise growth, and creating a scientific and technological innovation ecosystem. The Science and Technology Innovation Fund is jointly established by the Suzhou Industrial Park Financial Review Bureau as LP and Leading Venture Capital as GP. Focusing on strategic emerging industries such as biomedicine, nanotechnology applications, and artificial intelligence, we will adopt a combination of direct and allocated investment to support technology-based and innovative enterprises in the region to grow, improve, and strengthen.
Regarding Navigation in the New Territories:
Navigation New Territories was jointly founded by scientists, entrepreneurs, and senior investors in 2018, with a focus on venture capital in the fields of intelligent technology and biomedicine. Navigation New Territories has offices in Chongqing, Shanghai, San Francisco, and Boston, managing multiple RMB and USD funds with a scale of approximately RMB 2.8 billion. We are committed to realizing the value of hard technology by working alongside scientists and entrepreneurs, adhering to the principles of pragmatism and innovation, and jointly creating technology driven outstanding enterprises.